Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Seres Therapeutics (MCRB) over the last 11 years, with Q1 2025 value amounting to $32.7 million.

  • Seres Therapeutics' Net Income towards Common Stockholders rose 18143.42% to $32.7 million in Q1 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year decrease of 4578.03%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
  • Per Seres Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $32.7 million for Q1 2025, which was up 18143.42% from $139.8 million recorded in Q3 2024.
  • In the past 5 years, Seres Therapeutics' Net Income towards Common Stockholders ranged from a high of $139.8 million in Q3 2024 and a low of -$71.2 million during Q1 2023
  • Over the past 5 years, Seres Therapeutics' median Net Income towards Common Stockholders value was -$37.6 million (recorded in 2021), while the average stood at -$15.8 million.
  • As far as peak fluctuations go, Seres Therapeutics' Net Income towards Common Stockholders tumbled by 18795.63% in 2022, and later surged by 214431.93% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Net Income towards Common Stockholders stood at -$50.0 million in 2021, then tumbled by 37.59% to -$68.8 million in 2022, then surged by 90.51% to -$6.5 million in 2023, then soared by 2240.73% to $139.8 million in 2024, then plummeted by 76.62% to $32.7 million in 2025.
  • Its last three reported values are $32.7 million in Q1 2025, $139.8 million for Q3 2024, and -$32.9 million during Q2 2024.